NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub. The first application ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced Dual SET® Pulse Oximetry for Root®, a highly versatile patient monitoring and connectivity hub. The first application of ...

The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically Significant Bias Between Patients with Light ...

Improved SpO 2 Accuracy Now Available for All Patient Populations IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and ...

Masimo SET® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

Masimo today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh, Morocco, conducted the first Moroccan study on ...

In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones The INSPIRE Trial Prospectively Assesses Pulse ...

Masimo Corp.’s pulse oximetry technology avoids the dangerous under-recognition of low oxygen levels in people of color that plagues many pulse oximeters on the market, a peer-reviewed study in the ...